1
|
Wangmo C, Charoen N, Jantharapattana K,
Dechaphunkul A and Thongsuksai P: Epithelial-mesenchymal transition
predicts survival in oral squamous cell carcinoma. Pathol Oncol
Res. 26:1511–1518. 2020. View Article : Google Scholar : PubMed/NCBI
|
2
|
Huang F, Xin C, Lei K, Bai H, Li J and
Chen Q: Noncoding RNAs in oral premalignant disorders and oral
squamous cell carcinoma. Cell Oncol (Dordr). June 3–2020.(Epub
ahead of print). View Article : Google Scholar
|
3
|
Gharat SA, Momin M and Bhavsar C: Oral
squamous cell carcinoma: Current treatment strategies and
nanotechnology-based approaches for prevention and therapy. Crit
Rev Ther Drug Carrier Syst. 33:363–400. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Almangush A, Mäkitie AA, Triantafyllou A,
de Bree R, Strojan P, Rinaldo A, Hernandez-Prera JC, Suárez C,
Kowalski LP, Ferlito A and Leivo I: Staging and grading of oral
squamous cell carcinoma: An update. Oral Oncol. 107:1047992020.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hauptman N and Glavac D: MicroRNAs and
long non-coding RNAs: Prospects in diagnostics and therapy of
cancer. Radiol Oncol. 47:311–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Morris KV and Mattick JS: The rise of
regulatory RNA. Nat Rev Genet. 15:423–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Luo W, Wang M, Liu J, Cui X and Wang H:
Identification of a six lncRNAs signature as novel diagnostic
biomarkers for cervical cancer. J Cell Physiol. 235:993–1000. 2020.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Zhang H, Meng H, Huang X, Tong W, Liang X,
Li J, Zhang C and Chen M: lncRNA MIR4435-2HG promotes cancer cell
migration and invasion in prostate carcinoma by upregulating
TGF-β1. Oncol Lett. 18:4016–4021. 2019.PubMed/NCBI
|
11
|
Yang C, Li H, Zhang T, Chu Y, Chen D and
Zuo J: miR-200c overexpression inhibits the invasion and
tumorigenicity of epithelial ovarian cancer cells by suppressing
lncRNA HOTAIR in mice. J Cell Biochem. 121:1514–1523. 2020.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang J, Sui S, Wu H, Zhang J, Zhang X, Xu
S and Pang D: The transcriptional landscape of lncRNAs reveals the
oncogenic function of LINC00511 in ER-negative breast cancer. Cell
Death Dis. 10:5992019. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhu G, Wang S, Chen J, Wang Z, Liang X,
Wang X, Jiang J, Lang J and Li L: Long noncoding RNA HAS2-AS1
mediates hypoxia-induced invasiveness of oral squamous cell
carcinoma. Mol Carcinog. 56:2210–2222. 2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kong J, Sun W, Zhu W, Liu C, Zhang H and
Wang H: Long noncoding RNA LINC01133 inhibits oral squamous cell
carcinoma metastasis through a feedback regulation loop with GDF15.
J Surg Oncol. 118:1326–1334. 2018. View Article : Google Scholar : PubMed/NCBI
|
15
|
Jin Z, Jiang S, Jian S and Shang Z: Long
noncoding RNA MORT overexpression inhibits cancer cell
proliferation in oral squamous cell carcinoma by downregulating
ROCK1. J Cell Biochem. Feb 25–2019.(Epub ahead of print).
View Article : Google Scholar
|
16
|
Song T, Yan L, Cai K, Zhao T and Xu M:
Downregulation of long noncoding RNA PVT1 attenuates paclitaxel
resistance in glioma cells. Cancer Biomark. 23:447–453. 2018.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Shang AQ, Wang WW, Yang YB, Gu CZ, Ji P,
Chen C, Zeng BJ, Wu JL, Lu WY, Sun ZJ and Li D: Knockdown of long
noncoding RNA PVT1 suppresses cell proliferation and invasion of
colorectal cancer via upregulation of microRNA-214-3p. Am J Physiol
Gastrointest Liver Physiol. 317:G222–G232. 2019. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J,
Zhou Z, Zhang W, Qin L and Huang G: LncRNA PVT1 promotes
angiogenesis via activating the STAT3/VEGFA axis in gastric cancer.
Oncogene. 37:4094–4109. 2018. View Article : Google Scholar : PubMed/NCBI
|
19
|
Yang Q, Yu Y, Sun Z and Pan Y: Long
non-coding RNA PVT1 promotes cell proliferation and invasion
through regulating miR-133a in ovarian cancer. Biomed Pharmacother.
106:61–67. 2018. View Article : Google Scholar : PubMed/NCBI
|
20
|
Chen J, Yu Y, Li H, Hu Q, Chen X, He Y,
Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes
tumor progression by regulating the miR-143/HK2 axis in gallbladder
cancer. Mol Cancer. 18:332019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yan C, Chen Y, Kong W, Fu L, Liu Y, Yao Q
and Yuan Y: PVT1-derived miR-1207-5p promotes breast cancer cell
growth by targeting STAT6. Cancer Sci. 108:868–876. 2017.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Dejene SB, Ohman AW, Du W, Randhawa D,
Bradley A, Yadav N, Elias KM, Dinulescu DM and Setlur SR: Defining
fallopian tube-derived miRNA cancer signatures. Cancer Med.
8:6709–6716. 2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhong G, Lou W, Yao M, Du C, Wei H and Fu
P: Identification of novel mRNA-miRNA-lncRNA competing endogenous
RNA network associated with prognosis of breast cancer.
Epigenomics. 11:1501–1518. 2019. View Article : Google Scholar : PubMed/NCBI
|
24
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
25
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Khan AQ, Ahmed EI, Elareer NR, Junejo K,
Steinhoff M and Uddin S: Role of miRNA-regulated cancer stem cells
in the pathogenesis of human malignancies. Cells. 8:8402019.
View Article : Google Scholar
|
27
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Tay Y, Kats L, Salmena L, Weiss D, Tan SM,
Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al:
Coding-independent regulation of the tumor suppressor PTEN by
competing endogenous mRNAs. Cell. 147:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Zhang S, Liao K, Miao Z, Wang Q, Miao Y,
Guo Z, Qiu Y, Chen B, Ren L, Wei Z, et al: CircFOXO3 promotes
glioblastoma progression by acting as a competing endogenous RNA
for NFAT5. Neuro-oncol. 21:1284–1296. 2019. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wang H, Sha L, Huang L, Yang S, Zhou Q,
Luo X and Shi B: LINC00261 functions as a competing endogenous RNA
to regulate BCL2L11 expression by sponging miR-132-3p in
endometriosis. Am J Transl Res. 11:2269–2279. 2019.PubMed/NCBI
|
31
|
Cao C, Xu Y, Du K, Mi C, Yang C, Xiang L,
Xie Y and Liu W: LINC01303 functions as a competing endogenous RNA
to regulate EZH2 expression by sponging miR-101-3p in gastric
cancer. J Cell Mol Med. 23:7342–7348. 2019. View Article : Google Scholar : PubMed/NCBI
|
32
|
Yan J, Jia Y, Chen H, Chen W and Zhou X:
Long non-coding RNA PXN-AS1 suppresses pancreatic cancer
progression by acting as a competing endogenous RNA of miR-3064 to
upregulate PIP4K2B expression. J Exp Clin Cancer Res. 38:3902019.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhang S, Dong X, Ji T, Chen G and Shan L:
Long non-coding RNA UCA1 promotes cell progression by acting as a
competing endogenous RNA of ATF2 in prostate cancer. Am J Transl
Res. 9:366–375. 2017.PubMed/NCBI
|
34
|
Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H,
Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673
regulated non-small cell lung cancer proliferation, migration,
invasion and epithelial mesenchymal transition by sponging
miR-150-5p. Mol Cancer. 16:1182017. View Article : Google Scholar : PubMed/NCBI
|
35
|
Dai FQ, Li CR, Fan XQ, Tan L, Wang RT and
Jin H: miR-150-5p inhibits non-small-cell lung cancer metastasis
and recurrence by targeting HMGA2 and β-catenin signaling. Mol Ther
Nucleic Acids. 16:675–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
36
|
Chen X, Xu X, Pan B, Zeng K, Xu M, Liu X,
He B, Pan Y, Sun H and Wang S: miR-150-5p suppresses tumor
progression by targeting VEGFA in colorectal cancer. Aging (Albany
NY). 10:3421–3437. 2018. View Article : Google Scholar : PubMed/NCBI
|
37
|
Al-Maghrabi JA, Qureshi IA and Khabaz MN:
Immunhistochemical expression of GLUT1 is associated with low grade
and low stage of urinary bladder cancer. Int J Clin Exp Pathol.
12:3049–3057. 2019.PubMed/NCBI
|
38
|
Lee SY and Park JY: GLUT1 variants for
predicting prognosis after surgery in non-small cell lung cancer.
Ann Surg Oncol. 25 (Suppl 3):S948–S949. 2018. View Article : Google Scholar
|
39
|
Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao
X, Wen X and Chen J: GLUT1 regulates cell glycolysis and
proliferation in prostate cancer. Prostate. 78:86–94. 2018.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
42
|
Mueckler M and Thorens B: The SLC2 (GLUT)
family of membrane transporters. Mol Aspects Med. 34:121–138. 2013.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Deng D and Yan N: GLUT, SGLT, and SWEET:
Structural and mechanistic investigations of the glucose
transporters. Protein Sci. 25:546–558. 2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Smolková K, Bellance N, Scandurra F, Génot
E, Gnaiger E, Plecitá-Hlavatá L, Jezek P and Rossignol R:
Mitochondrial bioenergetic adaptations of breast cancer cells to
aglycemia and hypoxia. J Bioenerg Biomembr. 42:55–67. 2010.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Baffy G: Mitochondrial uncoupling in
cancer cells: Liabilities and opportunities. Biochim Biophys Acta
Bioenerg. 1858:655–664. 2017. View Article : Google Scholar : PubMed/NCBI
|
46
|
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian
Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al: A small-molecule
inhibitor of glucose transporter 1 downregulates glycolysis,
induces cell-cycle arrest, and inhibits cancer cell growth in vitro
and in vivo. Mol Cancer Ther. 11:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
|
47
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
48
|
Zambrano A, Molt M, Uribe E and Salas M:
Glut 1 in cancer cells and the inhibitory action of resveratrol as
a potential therapeutic strategy. Int J Mol Sci. 20:33742019.
View Article : Google Scholar
|
49
|
Samudio I, Harmancey R, Fiegl M,
Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W,
Duvvuri S, Taegtmeyer H and Andreeff M: Pharmacologic inhibition of
fatty acid oxidation sensitizes human leukemia cells to apoptosis
induction. J Clin Invest. 120:142–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
50
|
Vélez J, Hail N Jr, Konopleva M, Zeng Z,
Kojima K, Samudio I and Andreeff M: Mitochondrial uncoupling and
the reprograming of intermediary metabolism in leukemia cells.
Front Oncol. 3:672013. View Article : Google Scholar : PubMed/NCBI
|